US FDA strengthens renal warnings for diabetes products

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1607卷 / 1期

关键词：

D O I：

10.1007/s40278-016-18580-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：6 / 6

相关论文

共 50 条

[21] Wallcur's simulated/training IV NaCl products: more FDA warnings
Reactions Weekly, 2015, 1535 (1) : 7 - 7
[22] The FDA and New Safety Warnings
Moore, Thomas J.
Singh, Sonal
Furberg, Curt D.
ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (01) : 78 - 80
[23] US FDA approves marketing of diabetes test
Heseltine, Phoebe
BIOANALYSIS, 2013, 5 (13) : 1615 - 1615
[24] FDA backs rosiglitazone - with warnings
Tanne, Janice Hopkins
BRITISH MEDICAL JOURNAL, 2007, 335 (7613): : 223 - 223
[25] FDA Strengthens Supply of Cancer Drugs
不详
US PHARMACIST, 2012, 37 (04) : 44 - 44
[26] Impurity Testing of Ranitidine Products: US FDA Update
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 70 - 70
[27] Impurity testing of ranitidine products: US FDA update
Reactions Weekly, 2019, 1779 (1) : 1 - 1
[28] US Manufacturing Strengthens
Koenig, Bill
MANUFACTURING ENGINEERING, 2017, 158 (04): : 20 - 22
[29] FDA requires steroid growth warnings
不详
LANCET, 1998, 352 (9142): : 1760 - 1760
[30] US FDA warns of unauthorised devices for diabetes control
Reactions Weekly, 2019, 1755 (1) : 8 - 8

← 1 2 3 4 5 →